Skip to main content

Rho kinase inhibitor fasudil suppresses migration and invasion though down-regulating the expression of VEGF in lung cancer cell line A549

Medical Oncology volume 28, pages 565–571 (2011)Cite this article

Abstract

Rho and Rho-associated kinase play an important role in focal adhesion, stress fiber formation and cell motility. Fasudil is a kind of Rho kinase inhibitor. The effect and precise molecular mechanism of fasudil on the biology behavior of lung cancer cell A549 remains unclear. The cytotoxic effect of fasudil on A549 cell was measured by 3-(4, 5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay. Wound-healing assay was used to evaluate the effect of fasudil on migration activity of A549 cells. The invasion activity of A549 cells was detected by transwell chamber assay. The expression of MMPs was measured by gelatin zymography. RT-PCR and western blot were used to investigate the molecular change of A549 cells after treated with fasudil. Fasudil-inhibited proliferation of A549 cells in a concentration-dependent manner, decreased the migration and invasion activity. After treated with fasudil, the expression of MMP-2 and MMP-9 was significantly inhibited compared with the control group. Furthermore, the expression of RhoA and VEGF of A549 cell treated with fasudil was significantly down-regulated. Our findings indicate that fasudil might have a therapeutic potential for lung cancer though inhibiting cell proliferation, migration, invasion, MMPs activity and down-regulating the expression of RhoA and VEGF.

This is a preview of subscription content, access via your institution.

Access options

Buy single article

Instant access to the full article PDF.

43,34 €

Price includes VAT (Finland)
Tax calculation will be finalised during checkout.

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5

References

  1. Greenlee RT, Hill-Harmon MB, Murray T, Thun M. Cancer statistics. CA Cancer J Clin. 2001;51:15–36.

    PubMed  Article  CAS  Google Scholar 

  2. Hall A. Rho GTPases and the actin cytoskeleton. Science. 1998;279:509–14.

    PubMed  Article  CAS  Google Scholar 

  3. Fritz G, Brachetti C, Bahlmann F, Schmidt M, Kaina B. Rho GTPases in human breast tumours: expression and mutation analyses and correlation with clinical parameters. Br J Cancer. 2002;87:635–44.

    PubMed  Article  CAS  Google Scholar 

  4. Kamai T, Tsujii T, Arai K, Takagi K, Asami H, et al. Significant association of Rho/ROCK pathway with invasion and metastasis of bladder cancer. Clin Cancer Res. 2003;9:2632–41.

    PubMed  CAS  Google Scholar 

  5. Zohrabian VM, Forzani B, Chau Z, Murali R, Jhanwar-Uniyal M. Rho/ROCK and MAPK signaling pathways are involved in glioblastoma cell migration and proliferation. Anticancer Res. 2009;29:119–23.

    PubMed  CAS  Google Scholar 

  6. Kamai T, Arai K, Tsujii T, Honda M, Yoshida K. Overexpression of RhoA mRNA is associated with advanced stage in testicular germ cell tumour. BJU Int. 2001;87:227–31.

    PubMed  Article  CAS  Google Scholar 

  7. Wang HB, Liu XP, Liang J, Yang K, Sui AH, et al. Expression of RhoA and RhoC in colorectal carcinoma and its relations with clinicopathological parameters. Clin Chem Lab Med. 2009;47:811–7.

    PubMed  Article  CAS  Google Scholar 

  8. Fritz G, Just I, Kaina B. Rho GTPases are overexpressed in human tumors. Int J Cancer. 1999;81:682–7.

    PubMed  Article  CAS  Google Scholar 

  9. Sasaki Y, Suzuki M, Hidaka H. The novel and specific Rho-kinase inhibitor (S)-(+)-2-methyl-1-[(4-methyl-5-isoquinoline)sulfonyl]-homopiperazine as a probing molecule for Rho-kinase-involved pathway. Pharmacol Ther. 2002;93:225–32.

    PubMed  Article  CAS  Google Scholar 

  10. Yang X, Liu Y, Zong Z, Tian D. The Rho kinase inhibitor fasudil inhibits the migratory behaviour of 95-D lung carcinoma cells. Biomed Pharmacother. 2010;64:58–62.

    PubMed  Article  CAS  Google Scholar 

  11. Yin L, Morishige K, Takahashi T, Hashimoto K, Ogata S, et al. Fasudil inhibits vascular endothelial growth factor-induced angiogenesis in vitro and in vivo. Mol Cancer Ther. 2007;6:1517–25.

    PubMed  Article  CAS  Google Scholar 

  12. Kleiner DE, Stetler-Stevenson WG. Matrix metalloproteinases and metastasis. Cancer Chemother Pharmacol. 1999;43(Suppl):S42–51.

    PubMed  Article  CAS  Google Scholar 

  13. Lochter A, Bissell MJ. An odyssey from breast to bone: multi-step control of mammary metastases and osteolysis by matrix metalloproteinases. APMIS. 1999;107:128–36.

    PubMed  Article  CAS  Google Scholar 

  14. Corcoran ML, Hewitt RE, Kleiner DE, Stetler-Stevenson WG. MMP-2: expression, activation and inhibition. Enzyme Protein. 1996;49:7–19.

    PubMed  CAS  Google Scholar 

  15. Gohji K, Fujimoto N, Hara I, Fujii A, Gotoh A, et al. Serum matrix metalloproteinase-2 and its density in men with prostate cancer as a new predictor of disease extension. Int J Cancer. 1998;79:96–101.

    PubMed  Article  CAS  Google Scholar 

  16. Moses MA, Wiederschain D, Loughlin KR, Zurakowski D, Lamb CC, et al. Increased incidence of matrix metalloproteinases in urine of cancer patients. Cancer Res. 1998;58:1395–9.

    PubMed  CAS  Google Scholar 

  17. Rundhaug JE. Matrix metalloproteinases and angiogenesis. J Cell Mol Med. 2005;9:267–85.

    PubMed  Article  CAS  Google Scholar 

  18. Laack E, Scheffler A, Burkholder I, Boeters I, Andritzky B, Schuch G, et al. Pretreatment vascular endothelial growth factor (VEGF) and matrix metalloproteinase-9 (MMP-9) serum levels in patients with metastatic non-small cell lung cancer (NSCLC). Lung Cancer. 2005;50(1):51–8.

    PubMed  Article  Google Scholar 

  19. Folkman J. Tumor angiogenesis: therapeutic implications. N Engl J Med. 1971;285:1182–6.

    PubMed  Article  CAS  Google Scholar 

  20. Leung DW, Cachianes G, Kuang WJ, Goeddel DV, Ferrara N. Vascular endothelial growth factor is a secreted angiogenic mitogen. Science. 1989;246:1306–9.

    PubMed  Article  CAS  Google Scholar 

  21. Rousseau S, Houle F, Landry J, Huot J. p38MAP kinase activation by vascular endothelial growth factor mediates actin reorganization and cell migration in human endothelial cells. Oncogene. 1997;15:2169–77.

    PubMed  Article  CAS  Google Scholar 

  22. Hashimoto G, Inoki I, Fujii Y, Aoki T, Ikeda E, et al. Matrix metalloproteinases cleave connective tissue growth factor and reactivate angiogenic activity of vascular endothelial growth factor 165. J Biol Chem. 2002;277:36288–95.

    PubMed  Article  CAS  Google Scholar 

  23. Tachibana E, Harada T, Shibuya M, Saito K, Takayasu M, et al. Intra-arterial infusion of fasudil hydrochloride for treating vasospasm following subarachnoid haemorrhage. Acta Neurochir (Wien). 1999;141:13–9.

    Article  CAS  Google Scholar 

  24. Ralph MV, Bernard C, Deborah K, William BS, Steven G, et al. Efficacy and safety of fasudil in patients with stable angina: a double-bind, placebo-controlled, phase 2 trial. J Am Coll Cardiol. 2005;46:1803–11.

    Article  Google Scholar 

Download references

Author information

Affiliations

  1. Department of Oncology, The Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, 430022, Wuhan, China

    Fang Zhu, Zhe Zhang, Gang Wu, Zhenyu Li, Ruiguang Zhang, Jinghua Ren & Li Nong

Authors
  1. Fang Zhu
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Zhe Zhang
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Gang Wu
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Zhenyu Li
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Ruiguang Zhang
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Jinghua Ren
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Li Nong
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Gang Wu.

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Zhu, F., Zhang, Z., Wu, G. et al. Rho kinase inhibitor fasudil suppresses migration and invasion though down-regulating the expression of VEGF in lung cancer cell line A549. Med Oncol 28, 565–571 (2011). https://doi.org/10.1007/s12032-010-9468-5

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12032-010-9468-5

Keywords

  • Fasudil
  • RhoA
  • Migration
  • Invasion
  • Lung cancer